Teruo Nishida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Teruo Nishida has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Ken Fukuda
Department of Ophthalmology and Visual Science, Kochi Medical School, Kochi University, Nankoku City, Kochi, Japan
9 shared publications Ryoji Yanai
6 shared publications- Naoki Kumagai
Department of Ophthalmology, Yamaguchi University School of Medicine, Japan
4 shared publications Naoyuki Morishige
4 shared publicationsTai-Ichiro Chikama
Yamaguchi University Hospital
4 shared publicationsYang Liu
Department of Ophthalmology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan
4 shared publications
Latest Publications
- Open Access
- 23 August 2017
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 18 (9) , 1831
Corneal Fibroblasts as Sentinel Cells and Local Immune Modulators in Infectious Keratitis
The cornea serves as a barrier to protect the eye against external insults including microbial pathogens and antigens. Bacterial infection of the cornea often results in corneal melting and scarring that can lead to severe visual impairment. Not only live bacteria but also their components such as lipopolysaccharide (LPS) of Gram-negative bacteria contribute to the development of inflammation and subsequent corneal damage in infectious keratitis. We describe the important role played by corneal stromal fibroblasts (activated keratocytes) as sentinel cells, immune modulators, and effector cells in infectious keratitis. Corneal fibroblasts sense bacterial infection through Toll-like receptor (TLR)–mediated detection of a complex of LPS with soluble cluster of differentiation 14 (CD14) and LPS binding protein present in tear fluid. The cells then initiate innate immune responses including the expression of chemokines and adhesion molecules that promote the recruitment of inflammatory cells necessary for elimination of the infecting bacteria. Infiltrated neutrophils are activated by corneal stromal collagen and release mediators that stimulate the production of pro–matrix metalloproteinases by corneal fibroblasts. Elastase produced by Pseudomonas aeruginosa (P. aeruginosa) activates these released metalloproteinases, resulting in the degradation of stromal collagen. The modulation of corneal fibroblast activation and of the interaction of these cells with inflammatory cells and bacteria is thus important to minimize corneal scarring during treatment of infectious keratitis. Pharmacological agents that are able to restrain such activities of corneal fibroblasts without allowing bacterial growth represent a potential novel treatment option for prevention of excessive scarring and tissue destruction in the cornea.
- 23 August 2017
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 18 (9) , 1831
Open AccessCorneal Fibroblasts as Sentinel Cells and Local Immune Modulators in Infectious Keratitis
The cornea serves as a barrier to protect the eye against external insults including microbial pathogens and antigens. Bacterial infection of the cornea often results in corneal melting and scarring that can lead to severe visual impairment. Not only live bacteria but also their components such as lipopolysaccharide (LPS) of Gram-negative bacteria contribute to the development of inflammation and subsequent corneal damage in infectious keratitis. We describe the important role played by corneal stromal fibroblasts (activated keratocytes) as sentinel cells, immune modulators, and effector cells in infectious keratitis. Corneal fibroblasts sense bacterial infection through Toll-like receptor (TLR)–mediated detection of a complex of LPS with soluble cluster of differentiation 14 (CD14) and LPS binding protein present in tear fluid. The cells then initiate innate immune responses including the expression of chemokines and adhesion molecules that promote the recruitment of inflammatory cells necessary for elimination of the infecting bacteria. Infiltrated neutrophils are activated by corneal stromal collagen and release mediators that stimulate the production of pro–matrix metalloproteinases by corneal fibroblasts. Elastase produced by Pseudomonas aeruginosa (P. aeruginosa) activates these released metalloproteinases, resulting in the degradation of stromal collagen. The modulation of corneal fibroblast activation and of the interaction of these cells with inflammatory cells and bacteria is thus important to minimize corneal scarring during treatment of infectious keratitis. Pharmacological agents that are able to restrain such activities of corneal fibroblasts without allowing bacterial growth represent a potential novel treatment option for prevention of excessive scarring and tissue destruction in the cornea.
- 27 July 2012
- Published by Springer Nature in Japanese Journal of Ophthalmology
- Vol. 56 (5) , 417-431
The role of fibronectin in corneal wound healing explored by a physician–scientist
For the past 30 years, I have worked as a physician–scientist in both the clinic and laboratory setting at a number of university medical schools. Encountering patients in the clinic for whom treatment was not available led me to the laboratory in an attempt to develop the appropriate treatment for future patients. The main focus of my translational research has been the role of fibronectin in corneal epithelial wound healing and the development of fibronectin eyedrops for the treatment of patients with persistent corneal epithelial defects. An extension of this research led to the development of eyedrops containing the synthetic peptide proline–histidine–serine–arginine–asparagine (PHSRN), which corresponds to the second cell-binding site of fibronectin. My clinical experience with fibronectin eyedrops also prompted me to examine the role of the sensory neurotransmitter substance P and insulin-like growth factor-1 (IGF-1) in corneal wound healing, leading to the development of eyedrops containing peptides derived from these agents (peptides FGLM-amide and SSSR, respectively). Although the path from the laboratory to the clinic in these instances has been relatively short, the time required to establish the newly identified treatment modalities in the wider community has been long. In this review, I relate the trajectory of my translational research career.
- 27 July 2012
- Published by Springer Nature in Japanese Journal of Ophthalmology
- Vol. 56 (5) , 417-431
The role of fibronectin in corneal wound healing explored by a physician–scientist
For the past 30 years, I have worked as a physician–scientist in both the clinic and laboratory setting at a number of university medical schools. Encountering patients in the clinic for whom treatment was not available led me to the laboratory in an attempt to develop the appropriate treatment for future patients. The main focus of my translational research has been the role of fibronectin in corneal epithelial wound healing and the development of fibronectin eyedrops for the treatment of patients with persistent corneal epithelial defects. An extension of this research led to the development of eyedrops containing the synthetic peptide proline–histidine–serine–arginine–asparagine (PHSRN), which corresponds to the second cell-binding site of fibronectin. My clinical experience with fibronectin eyedrops also prompted me to examine the role of the sensory neurotransmitter substance P and insulin-like growth factor-1 (IGF-1) in corneal wound healing, leading to the development of eyedrops containing peptides derived from these agents (peptides FGLM-amide and SSSR, respectively). Although the path from the laboratory to the clinic in these instances has been relatively short, the time required to establish the newly identified treatment modalities in the wider community has been long. In this review, I relate the trajectory of my translational research career.
- 11 November 2011
- Published by Springer Nature in Japanese Journal of Ophthalmology
- Vol. 56 (1) , 20-25
Differential contributions of impaired corneal sensitivity and reduced tear secretion to corneal epithelial disorders
To determine the possible roles of impaired corneal sensitivity and reduced tear secretion in various types of corneal epithelial disorders. A total of 99 patients (179 eyes) with corneal epithelial disorders classified as persistent epithelial defects (PED), corneal erosion, or superficial punctate keratopathy (SPK) and 115 individuals (230 eyes) without apparent ocular surface disorders (controls) were enrolled in a prospective study. Corneal sensitivity was measured with a Cochet-Bonnet esthesiometer, and tear secretion was measured by the Schirmer test in each subject. Corneal sensitivity of eyes in the PED and corneal erosion groups was significantly lower than that in the control group. Schirmer test values for eyes in the SPK group were significantly reduced compared with those in the control group. A loss of corneal sensitivity may contribute to the development of PED and corneal erosion, whereas reduced tear secretion may be a contributing factor for SPK. Both results indicate the importance of corneal sensory innervation to the maintenance of corneal integrity.
- 11 November 2011
- Published by Springer Nature in Japanese Journal of Ophthalmology
- Vol. 56 (1) , 20-25
Differential contributions of impaired corneal sensitivity and reduced tear secretion to corneal epithelial disorders
To determine the possible roles of impaired corneal sensitivity and reduced tear secretion in various types of corneal epithelial disorders. A total of 99 patients (179 eyes) with corneal epithelial disorders classified as persistent epithelial defects (PED), corneal erosion, or superficial punctate keratopathy (SPK) and 115 individuals (230 eyes) without apparent ocular surface disorders (controls) were enrolled in a prospective study. Corneal sensitivity was measured with a Cochet-Bonnet esthesiometer, and tear secretion was measured by the Schirmer test in each subject. Corneal sensitivity of eyes in the PED and corneal erosion groups was significantly lower than that in the control group. Schirmer test values for eyes in the SPK group were significantly reduced compared with those in the control group. A loss of corneal sensitivity may contribute to the development of PED and corneal erosion, whereas reduced tear secretion may be a contributing factor for SPK. Both results indicate the importance of corneal sensory innervation to the maintenance of corneal integrity.
- 1 October 2011
- Published by Wolters Kluwer Health in Cornea
- Vol. 30 (10) , 1129-1134
Immunohistofluorescence Analysis of Myofibroblast Transdifferentiation in Human Corneas With Bullous Keratopathy
Purpose: To detect the transdifferentiation of keratocytes into myofibroblasts in human corneas with bullous keratopathy and to examine the relation of such transdifferentiation to the clinical course of the disease. Methods: Twenty patients with bullous keratopathy who underwent penetrating keratoplasty were enrolled in the study. Corneal buttons collected during surgery were examined for expression of α-smooth muscle actin (αSMA) by immunoblot analysis and by immunofluorescence analysis of whole-mount preparations. The course of bullous keratopathy was evaluated from clinical charts. Results: Immunoblot analysis revealed a marked increase in αSMA expression in some corneas affected by bullous keratopathy. Immunofluorescence analysis revealed that αSMA was expressed in myofibroblastic cells in the stroma of 10 of the 20 corneas examined. Expression of αSMA was detected in subjects with a clinical history of corneal epithelial erosion from 12 months after the onset of clinical stromal edema. In contrast, in subjects without a clinical history of epithelial erosion, αSMA expression was not detected until at least 27 months after the onset of stromal edema. The incidence of αSMA expression in stromal cells was not significantly associated with topical steroid administration. Conclusions: Transdifferentiation of keratocytes into myofibroblasts was observed in human corneas affected by bullous keratopathy. Such transdifferentiation occurred earlier after the onset of stromal edema in patients with a clinical history of epithelial erosion than in those without such a history.
- 1 October 2011
- Published by Wolters Kluwer Health in Cornea
- Vol. 30 (10) , 1129-1134
Immunohistofluorescence Analysis of Myofibroblast Transdifferentiation in Human Corneas With Bullous Keratopathy
Purpose: To detect the transdifferentiation of keratocytes into myofibroblasts in human corneas with bullous keratopathy and to examine the relation of such transdifferentiation to the clinical course of the disease. Methods: Twenty patients with bullous keratopathy who underwent penetrating keratoplasty were enrolled in the study. Corneal buttons collected during surgery were examined for expression of α-smooth muscle actin (αSMA) by immunoblot analysis and by immunofluorescence analysis of whole-mount preparations. The course of bullous keratopathy was evaluated from clinical charts. Results: Immunoblot analysis revealed a marked increase in αSMA expression in some corneas affected by bullous keratopathy. Immunofluorescence analysis revealed that αSMA was expressed in myofibroblastic cells in the stroma of 10 of the 20 corneas examined. Expression of αSMA was detected in subjects with a clinical history of corneal epithelial erosion from 12 months after the onset of clinical stromal edema. In contrast, in subjects without a clinical history of epithelial erosion, αSMA expression was not detected until at least 27 months after the onset of stromal edema. The incidence of αSMA expression in stromal cells was not significantly associated with topical steroid administration. Conclusions: Transdifferentiation of keratocytes into myofibroblasts was observed in human corneas affected by bullous keratopathy. Such transdifferentiation occurred earlier after the onset of stromal edema in patients with a clinical history of epithelial erosion than in those without such a history.
- 1 April 2011
- Vol. 115 (4) , 386-90
[Outcome of conjunctival autograft with amniotic membrane transplantation for recurrent pterygium].
To investigate the outcome of conjunctival autograft with amniotic membrane transplantation without the use of mitomycin C for cases of recurrent pterygium. Thirty-nine eyes of 35 patients (aged 27 to 76 years) who underwent the surgical procedure for recurrent pterygium at Yamaguchi University Hospital from November 1998 to July 2007 were evaluated retrospectively from their medical records. Patients who did not undergo postoperative follow-up examination for at least 6 months were excluded. The mean number of prior surgeries was 2.9 (range, 2 to 10), and the mean +/- SD follow-up time was 42.0 +/- 29.6 months. Twenty seven of 29 eyes (93.1%) with recurrent grade 3 pterygium showed a reduction in the size of the new growth after surgery. The symblepharon improved postoperatively in 5 of 15 eyes (33.3%) and restriction of ocular movement improved in 11 of 24 eyes (45.8%). Most recurrences occurred within 6 months after surgery, although one case did not show a recurrence until 2 years postsurgery. Conjunctival autograft with amniotic membrane transplantation without the use of mitomycin C reduced the size of the recurrent pterygium. However, 6 of the 16 eyes (37.5%) required subsequent surgery, suggesting that the procedure has limitations. Mitomycin C should therefore possibly be considered for cases with severe symblepharon or restriction of ocular movement. In choosing the surgical procedure for recurrent pterygium, diplopia can be an important indicator of the severity of a symblepharon or restriction of ocular movement.
- 1 April 2011
- Vol. 115 (4) , 386-90
[Outcome of conjunctival autograft with amniotic membrane transplantation for recurrent pterygium].
To investigate the outcome of conjunctival autograft with amniotic membrane transplantation without the use of mitomycin C for cases of recurrent pterygium. Thirty-nine eyes of 35 patients (aged 27 to 76 years) who underwent the surgical procedure for recurrent pterygium at Yamaguchi University Hospital from November 1998 to July 2007 were evaluated retrospectively from their medical records. Patients who did not undergo postoperative follow-up examination for at least 6 months were excluded. The mean number of prior surgeries was 2.9 (range, 2 to 10), and the mean +/- SD follow-up time was 42.0 +/- 29.6 months. Twenty seven of 29 eyes (93.1%) with recurrent grade 3 pterygium showed a reduction in the size of the new growth after surgery. The symblepharon improved postoperatively in 5 of 15 eyes (33.3%) and restriction of ocular movement improved in 11 of 24 eyes (45.8%). Most recurrences occurred within 6 months after surgery, although one case did not show a recurrence until 2 years postsurgery. Conjunctival autograft with amniotic membrane transplantation without the use of mitomycin C reduced the size of the recurrent pterygium. However, 6 of the 16 eyes (37.5%) required subsequent surgery, suggesting that the procedure has limitations. Mitomycin C should therefore possibly be considered for cases with severe symblepharon or restriction of ocular movement. In choosing the surgical procedure for recurrent pterygium, diplopia can be an important indicator of the severity of a symblepharon or restriction of ocular movement.
- 1 September 2010
- Published by Wolters Kluwer Health in Eye & Contact Lens: Science & Clinical Practice
- Vol. 36 (5) , 300-304
Translational Research in Corneal Epithelial Wound Healing
To review both the roles of fibronectin and the sensory neurotransmitter substance P in corneal epithelial wound healing and the clinical application of these agents to treat persistent corneal epithelial defects. Fibronectin is expressed at the site of corneal epithelial defects, serves as a provisional matrix for the migration of epithelial cells, and stimulates epithelial wound healing in vitro and in animal models. Eyedrops containing autologous plasma fibronectin are also effective for the treatment of persistent epithelial defects of the cornea in patients. Substance P and insulin-like growth factor-1 synergistically stimulate corneal epithelial wound healing in vitro and in animal models. Furthermore, the administration of eyedrops containing both a substance P-derived peptide (FGLM-amide) and insulin-like growth factor-1-derived peptide (SSSR) is effective for the treatment of persistent epithelial defects in individuals with neurotrophic keratopathy. Basic research on the mechanism of corneal epithelial wound healing has the potential to lead to the development of new modes of treatment for persistent corneal epithelial defects. Clinical experience with eyedrops containing fibronectin or both FGLM-amide and SSSR has highlighted the importance of the basement membrane and neural stimuli in maintenance of the integrity of the normal corneal epithelium.
- 1 September 2010
- Published by Wolters Kluwer Health in Eye & Contact Lens: Science & Clinical Practice
- Vol. 36 (5) , 300-304
Translational Research in Corneal Epithelial Wound Healing
To review both the roles of fibronectin and the sensory neurotransmitter substance P in corneal epithelial wound healing and the clinical application of these agents to treat persistent corneal epithelial defects. Fibronectin is expressed at the site of corneal epithelial defects, serves as a provisional matrix for the migration of epithelial cells, and stimulates epithelial wound healing in vitro and in animal models. Eyedrops containing autologous plasma fibronectin are also effective for the treatment of persistent epithelial defects of the cornea in patients. Substance P and insulin-like growth factor-1 synergistically stimulate corneal epithelial wound healing in vitro and in animal models. Furthermore, the administration of eyedrops containing both a substance P-derived peptide (FGLM-amide) and insulin-like growth factor-1-derived peptide (SSSR) is effective for the treatment of persistent epithelial defects in individuals with neurotrophic keratopathy. Basic research on the mechanism of corneal epithelial wound healing has the potential to lead to the development of new modes of treatment for persistent corneal epithelial defects. Clinical experience with eyedrops containing fibronectin or both FGLM-amide and SSSR has highlighted the importance of the basement membrane and neural stimuli in maintenance of the integrity of the normal corneal epithelium.
- 1 July 2009
- Published by Wolters Kluwer Health in Current Opinion in Ophthalmology
- Vol. 20 (4) , 276-281
Advances in treatment for neurotrophic keratopathy
To review the clinical characteristics and possible new mode of treatments for the corneal epithelial disorders associated with neurotrophic keratopathy. The successful clinical applications of eyedrops containing substance P and insulin-like growth factor-1, or peptides derived therefrom, were reported for the treatment of humans with neurotrophic keratopathy. Neurotrophic keratopathy, a degenerative disease of the cornea, is caused by an impairment of function of the trigeminal nerve and an insufficient supply of neural factors. The combination of substance P, a sensory neurotransmitter, and insulin-like growth factor-1 induced a synergistic stimulatory effect on corneal epithelial migration as well as on corneal wound closure in vivo. We discuss the roles of growth factors and substance P, a sensory neurotransmitter released from the trigeminal nerve, in corneal epithelial wound healing as well as the clinical application of these molecules to the treatment of neurotrophic keratopathy.
- 1 July 2009
- Published by Wolters Kluwer Health in Current Opinion in Ophthalmology
- Vol. 20 (4) , 276-281
Advances in treatment for neurotrophic keratopathy
To review the clinical characteristics and possible new mode of treatments for the corneal epithelial disorders associated with neurotrophic keratopathy. The successful clinical applications of eyedrops containing substance P and insulin-like growth factor-1, or peptides derived therefrom, were reported for the treatment of humans with neurotrophic keratopathy. Neurotrophic keratopathy, a degenerative disease of the cornea, is caused by an impairment of function of the trigeminal nerve and an insufficient supply of neural factors. The combination of substance P, a sensory neurotransmitter, and insulin-like growth factor-1 induced a synergistic stimulatory effect on corneal epithelial migration as well as on corneal wound closure in vivo. We discuss the roles of growth factors and substance P, a sensory neurotransmitter released from the trigeminal nerve, in corneal epithelial wound healing as well as the clinical application of these molecules to the treatment of neurotrophic keratopathy.
- 1 April 2009
- Published by Wiley in Cell Biology International
- Vol. 33 (4) , 534-541
Treatment with FTY720 during the induction or effector phase suppresses the development of experimental allergic conjunctivitis in mice
Purpose: To investigate whether experimental allergic conjunctivitis (EC) can be suppressed by treatment with the immunomodulatory drug FTY720, which reduces the recruitment of effector T cells into inflammatory sites. Methods: BALB/c mice were actively immunized with ragweed (RW) and then injected intraperitoneally with FTY720 on days 0, 2, 4, 6 and 8 (induction phase treatment) followed by challenge on day 10 with RW‐containing eye drops. Alternatively, naïve mice that received RW‐primed splenocytes were injected intraperitoneally with FTY720 on days 2 and 4 (effector phase treatment) followed by RW challenge on day 4. Twenty‐four hours after RW challenge, conjunctivas and spleens were harvested for histology or immunohistochemistry, and flow cytometric analysis or cytokine assays, respectively. Results: FTY720 treatment during the induction phase suppressed the conjunctival infiltration of T cells as well as eosinophils and macrophages. The splenocytes from induction phase‐treated mice contained significantly less CD4+ and CD8+ T cells and showed significant suppression of Th2 but not Th1 cytokine production. Effector phase treatment with FTY720 suppressed conjunctival eosinophil infiltration. Conclusions: These data demonstrate that FTY720 treatment during the induction phase decreases the absolute number of CD4+ and CD8+ T cells in the spleen and suppresses Th2 cytokine production by splenocytes. This leads to the suppression of EC. FTY720 treatment also suppresses EC when delivered during the effector phase. Thus, FTY720 treatment may be suitable for treating severe forms of vernal keratoconjunctivitis.
- 1 April 2009
- Published by Wiley in Cell Biology International
- Vol. 33 (4) , 534-541
Treatment with FTY720 during the induction or effector phase suppresses the development of experimental allergic conjunctivitis in mice
Purpose: To investigate whether experimental allergic conjunctivitis (EC) can be suppressed by treatment with the immunomodulatory drug FTY720, which reduces the recruitment of effector T cells into inflammatory sites. Methods: BALB/c mice were actively immunized with ragweed (RW) and then injected intraperitoneally with FTY720 on days 0, 2, 4, 6 and 8 (induction phase treatment) followed by challenge on day 10 with RW‐containing eye drops. Alternatively, naïve mice that received RW‐primed splenocytes were injected intraperitoneally with FTY720 on days 2 and 4 (effector phase treatment) followed by RW challenge on day 4. Twenty‐four hours after RW challenge, conjunctivas and spleens were harvested for histology or immunohistochemistry, and flow cytometric analysis or cytokine assays, respectively. Results: FTY720 treatment during the induction phase suppressed the conjunctival infiltration of T cells as well as eosinophils and macrophages. The splenocytes from induction phase‐treated mice contained significantly less CD4+ and CD8+ T cells and showed significant suppression of Th2 but not Th1 cytokine production. Effector phase treatment with FTY720 suppressed conjunctival eosinophil infiltration. Conclusions: These data demonstrate that FTY720 treatment during the induction phase decreases the absolute number of CD4+ and CD8+ T cells in the spleen and suppresses Th2 cytokine production by splenocytes. This leads to the suppression of EC. FTY720 treatment also suppresses EC when delivered during the effector phase. Thus, FTY720 treatment may be suitable for treating severe forms of vernal keratoconjunctivitis.
- 1 February 2009
- Vol. 113 (2) , 101-6
[Effect of preservative-free betamethasone sodium phosphate eyedrops on the development of corneal epithelial disorders after penetrating keratoplasty].
To investigate the effects of preservative-free eyedrops containing betamethasone sodium phosphate (BSP) on the development of corneal epithelial disorders after penetrating keratoplasty (PKP). The records of 48 patients who underwent unilateral PKP and were followed for 6 months postoperatively were reviewed retrospectively. Twenty-four patients were treated with BSP eyedrops containing preservatives and the other 24 patients with preservative-free BSP eyedrops four times daily. Patients in the two groups were matched for age and sex. Corneal epithelial disorders and other complications were examined with a slitlamp biomicroscope at 1, 3, and 6 months after surgery. None of the patients developed corneal erosion or corneal epithelial defects. The incidence of superficial punctate keratopathy in the preservative-free group (2 of 24 eyes) was significantly reduced compared with that in the preservative group (9 of 24 eyes) 1 month after surgery. The SPK score in the preservative-free group (0.17 +/- 0.56 points) was also significantly smaller than that in the preservative group (1.04 +/- 1.46 points) at 1 month. There was no significant difference in other postoperative complications between the two groups. Preservative-free BSP eyedrops are effective for preventing the development of corneal epithelial disorders after PKP.
- 1 February 2009
- Vol. 113 (2) , 101-6
[Effect of preservative-free betamethasone sodium phosphate eyedrops on the development of corneal epithelial disorders after penetrating keratoplasty].
To investigate the effects of preservative-free eyedrops containing betamethasone sodium phosphate (BSP) on the development of corneal epithelial disorders after penetrating keratoplasty (PKP). The records of 48 patients who underwent unilateral PKP and were followed for 6 months postoperatively were reviewed retrospectively. Twenty-four patients were treated with BSP eyedrops containing preservatives and the other 24 patients with preservative-free BSP eyedrops four times daily. Patients in the two groups were matched for age and sex. Corneal epithelial disorders and other complications were examined with a slitlamp biomicroscope at 1, 3, and 6 months after surgery. None of the patients developed corneal erosion or corneal epithelial defects. The incidence of superficial punctate keratopathy in the preservative-free group (2 of 24 eyes) was significantly reduced compared with that in the preservative group (9 of 24 eyes) 1 month after surgery. The SPK score in the preservative-free group (0.17 +/- 0.56 points) was also significantly smaller than that in the preservative group (1.04 +/- 1.46 points) at 1 month. There was no significant difference in other postoperative complications between the two groups. Preservative-free BSP eyedrops are effective for preventing the development of corneal epithelial disorders after PKP.